Dr. Hussein Bagha Delivers Keynote Address at International Cardiometabolic Forum in Beijing, China

Dr. Hussein Bagha had the privilege of presenting at the prestigious International Cardiometabolic Forum (ICMF) in Beijing, China. His presentation, titled "Should all patients with CKD and Diabetes Mellitus be on SGLT2 Inhibitors," sparked valuable discussions among attendees and garnered insights from international experts in the field.

Dr. Bagha's presentation addressed the critical intersection of chronic kidney disease (CKD) and diabetes mellitus, two conditions with significant implications for cardiovascular health. He explored the potential benefits of SGLT2 inhibitors in managing these comorbidities and their impact on patient outcomes.

The ICMF provided a unique platform for Dr. Bagha to engage with leading experts from around the globe, exchanging knowledge and best practices in cardiometabolic care. The experience was both enlightening and enriching, offering valuable perspectives that will inform Dr. Bagha's approach to patient care and research endeavors.

Reflecting on his participation in the forum, Dr. Bagha expressed gratitude for the opportunity to contribute to the dialogue surrounding cardiometabolic health. He emphasized the importance of collaborative efforts in advancing our understanding and management of complex medical conditions, ultimately leading to improved outcomes for patients worldwide.

Dr. Bagha's involvement in the ICMF highlights his commitment to staying at the forefront of medical advancements and leveraging international collaboration to enhance patient care. His presentation underscored the significance of individualized treatment approaches tailored to the unique needs of patients with CKD and diabetes mellitus.